These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9097802)
1. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Lane L; Tamesis R; Rodriguez A; Christen W; Akova YA; Messmer E; Pedroza-Seres M; Barney N; Foster CS Ophthalmology; 1995 Oct; 102(10):1530-5. PubMed ID: 9097802 [TBL] [Abstract][Full Text] [Related]
2. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Tamesis RR; Rodriguez A; Christen WG; Akova YA; Messmer E; Foster CS Ophthalmology; 1996 May; 103(5):768-75. PubMed ID: 8637685 [TBL] [Abstract][Full Text] [Related]
3. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044 [TBL] [Abstract][Full Text] [Related]
4. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. Kempen JH; Daniel E; Dunn JP; Foster CS; Gangaputra S; Hanish A; Helzlsouer KJ; Jabs DA; Kaçmaz RO; Levy-Clarke GA; Liesegang TL; Newcomb CW; Nussenblatt RB; Pujari SS; Rosenbaum JT; Suhler EB; Thorne JE BMJ; 2009 Jul; 339():b2480. PubMed ID: 19578087 [TBL] [Abstract][Full Text] [Related]
5. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Baker KB; Spurrier NJ; Watkins AS; Smith JR; Rosenbaum JT Br J Ophthalmol; 2006 Dec; 90(12):1481-5. PubMed ID: 16914474 [TBL] [Abstract][Full Text] [Related]
6. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Jabs DA; Rosenbaum JT; Foster CS; Holland GN; Jaffe GJ; Louie JS; Nussenblatt RB; Stiehm ER; Tessler H; Van Gelder RN; Whitcup SM; Yocum D Am J Ophthalmol; 2000 Oct; 130(4):492-513. PubMed ID: 11024423 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Masunaga Y; Ohno K; Ogawa R; Hashiguchi M; Echizen H; Ogata H Ann Pharmacother; 2007 Jan; 41(1):21-8. PubMed ID: 17200426 [TBL] [Abstract][Full Text] [Related]
8. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Zach H; Cetin H; Hilger E; Paul A; Wuschitz B; Jung R; Auff E; Zimprich F Eur J Neurol; 2013 Apr; 20(4):708-13. PubMed ID: 23279780 [TBL] [Abstract][Full Text] [Related]
9. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Kempen JH; Daniel E; Gangaputra S; Dreger K; Jabs DA; Kaçmaz RO; Pujari SS; Anzaar F; Foster CS; Helzlsouer KJ; Levy-Clarke GA; Nussenblatt RB; Liesegang T; Rosenbaum JT; Suhler EB Ophthalmic Epidemiol; 2008; 15(1):47-55. PubMed ID: 18300089 [TBL] [Abstract][Full Text] [Related]
11. Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome. Kiss S; Letko E; Qamruddin S; Baltatzis S; Foster CS Ophthalmology; 2003 Sep; 110(9):1764-9. PubMed ID: 13129875 [TBL] [Abstract][Full Text] [Related]
12. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Sultan SM; Ioannou Y; Isenberg DA Rheumatology (Oxford); 2000 Oct; 39(10):1147-52. PubMed ID: 11035137 [TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Kiss S; Ahmed M; Letko E; Foster CS Ophthalmology; 2005 Jun; 112(6):1066-71. PubMed ID: 15936442 [TBL] [Abstract][Full Text] [Related]
14. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine. Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for extraophthalmic involvement and treatment outcomes in patients with IgG4-related ophthalmic disease. Park J; Lee MJ; Kim N; Kim JE; Park SW; Choung HK; Khwarg SI Br J Ophthalmol; 2018 Jun; 102(6):736-741. PubMed ID: 28972022 [TBL] [Abstract][Full Text] [Related]